<p>根据公司在最近向证券交易委员会的披露，维吉尼亚退休系统等在第三季度减少了对礼来公司的股份，减幅为 15.7%。该机构投资者在季度内出售了 14,600 股后，持有 78,564 股公司的股票。在最近的报告期结束时，维吉尼亚退休系统等在礼来公司的持股价值为 59,944,000 美元。</p>
<p>获取 <strong>礼来公司</strong> 的提醒：</p>
<ul>
<li>FDA 批准诺和诺德的 Wegovy 药丸：2026 年的游戏规则改变者</li>
</ul>
<p>其他一些大型投资者也调整了他们对 LLY 的持股。Lazard Freres Gestion S.A.S.在第二季度将其在礼来公司的股份增加了 114.3%。Lazard Freres Gestion S.A.S.现在拥有 77,295 股公司的股票，价值为 60,253,000 美元，此前在上个季度购买了 41,222 股。Precedent Wealth Partners LLC 在第二季度将其在礼来公司的持股增加了 15.3%。Precedent Wealth Partners LLC 现在拥有 294 股公司的股票，价值为 229,000 美元，此前在上个季度增加了 39 股。中央太平洋银行信托部在第三季度将其在礼来公司的股份增加了 25.8%。中央太平洋银行信托部现在拥有 8,990 股公司的股票，价值为 6,859,000 美元，此前在上个季度增加了 1,843 股。Capital Advisors Inc. OK 在第二季度将其在礼来公司的股份增加了 6.8%。Capital Advisors Inc. OK 现在拥有 6,747 股公司的股票，价值为 5,260,000 美元，此前在上个季度增加了 429 股。最后，Family CFO Inc 在第二季度获得了礼来公司的新股份，价值约为 54,000 美元。机构投资者和对冲基金持有公司 82.53% 的股票。</p>
<h2>礼来公司的价格表现</h2>
<p>LLY 股票在周四开盘价为 1,075.00 美元。礼来公司的 52 周低点为 623.78 美元，52 周高点为 1,111.99 美元。该公司的速动比率为 1.24，流动比率为 1.55，债务与股本比率为 1.71。该股票的市值为 1.02 万亿美元，市盈率为 52.59，市盈率增长比率为 1.09，贝塔值为 0.37。该公司的 50 日移动平均线为 1,003.00 美元，200 日移动平均线为 846.93 美元。</p>
<ul>
<li>为什么华尔街放弃了辉瑞——这可能是个错误</li>
</ul>
<p>礼来公司（NYSE:LLY - 获取免费报告）最近在 10 月 30 日星期四发布了季度财报。该公司报告本季度每股收益为 7.02 美元，超出分析师一致预期的 6.42 美元，超出幅度为 0.60 美元。该公司本季度的收入为 176 亿美元，而分析师预期为 160.9 亿美元。礼来公司的股本回报率为 109.52%，净利润率为 30.99%。与去年同期相比，该公司的收入增长了 53.9%。在去年同期，该公司每股收益为 1.18 美元。礼来公司已将其 2025 财年的指导目标设定为 23.000-23.700 每股收益。整体来看，研究分析师预计礼来公司今年将发布 23.48 美元的每股收益。</p>
<h2>礼来公司增加股息</h2>
<p>该公司最近宣布了一项季度股息，将于 3 月 10 日星期二支付。记录在案的股东将在 2 月 13 日星期五获得每股 1.73 美元的股息。这比礼来公司之前的季度股息 1.50 美元有所增加。这相当于每年 6.92 美元的股息，股息收益率为 0.6%。除息日期为 2 月 13 日星期五。礼来公司的股息支付比率（DPR）为 29.35%。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>礼来的新药数据为 2026 年设定了高风险赌注</li>
</ul>
<p>几位研究分析师最近对 LLY 股票发表了看法。Sanford C. Bernstein 在 12 月 19 日星期五的报告中重申了对礼来公司股票的 “跑赢大盘” 评级。美国银行在 12 月 15 日的研究报告中将礼来公司的目标价从 1,286.00 美元下调至 1,268.00 美元，并对该股票给予 “买入” 评级。富国银行在 12 月 10 日的报告中将礼来公司的目标价从 1,100.00 美元上调至 1,200.00 美元，并给予该公司 “增持” 评级。汇丰银行在 12 月 10 日的研究报告中重申了 “持有” 评级，并对礼来公司的股票设定了 1,070.00 美元的目标价。最后，Cantor Fitzgerald 在 12 月 1 日的报告中重申了对礼来公司股票的 “增持” 评级。四位投资分析师对该股票给予了强烈买入评级，十七位给予了买入评级，五位给予了持有评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 1,155.36 美元。</p>
<p><strong>查看我们关于礼来公司的最新研究报告</strong></p>
<h2>礼来公司公司简介</h2>
<p>（免费报告）</p>
<p>礼来公司 NYSE: LLY 是一家成立于 1876 年的全球制药公司，总部位于印第安纳州印第安纳波利斯。该公司研究、开发、生产和商业化广泛的药物和疗法，服务于全球患者。礼来在北美、欧洲、亚洲及其他地区开展业务并拥有商业存在，服务于发达市场和新兴市场。近年来，该公司由总裁兼首席执行官 David A.领导。</p>
<h2>精选文章</h2>
<ul>
<li>我们更喜欢的五只股票胜过礼来公司</li>
<li>这个假期你花 1 美元能买到的最好东西</li>
<li>假期惊喜：1 美元让你拥有一切</li>
<li>美国 “最糟糕” 的圣诞促销</li>
<li>市场恐慌：特朗普刚刚对你的股票投下了一颗炸弹</li>
<li>你家族的财富将在 2026 年到期？</li>
</ul>
<p><strong>想知道其他对 LLY 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com 获取 Eli Lilly and Company (NYSE:LLY - 免费报告) 的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Eli Lilly and Company 吗？</h2>
<p>在考虑 Eli Lilly and Company 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Eli Lilly and Company 并不在名单上。</p>
<p>虽然 Eli Lilly and Company 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

礼来

<p>维吉尼亚退休系统等在第三季度将其在礼来公司（NYSE:LLY）的持股减少了 15.7%，在出售了 14,600 股后，持有 78,564 股。他们的持股价值为 5,994 万美元。其他投资者，包括 Lazard Freres Gestion S.A.S.和 Precedent Wealth Partners LLC，也调整了他们的持股。礼来的股票开盘价为 1,075.00 美元，市值为 1.02 万亿美元。该公司报告了上一季度每股收益为 7.02 美元，超出预期，并宣布将每股股息提高至 1.73 美元，自 3 月 10 日起生效</p>

<p>VIRGINIA RETIREMENT SYSTEMS ET Al reduced its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 15.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 78,564 shares of the company's stock after selling 14,600 shares during the quarter. VIRGINIA RETIREMENT SYSTEMS ET Al's holdings in Eli Lilly and Company were worth $59,944,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>根据公司在最近向证券交易委员会的披露，维吉尼亚退休系统等在第三季度减少了对礼来公司的股份，减幅为 15.7%。该机构投资者在季度内出售了 14,600 股后，持有 78,564 股公司的股票。在最近的报告期结束时，维吉尼亚退休系统等在礼来公司的持股价值为 59,944,000 美元。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>礼来公司</strong> 的提醒：</p>
</div><ul>
<li>FDA Approves Novo Nordisk's Wegovy Pill: A Game Changer for 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>FDA 批准诺和诺德的 Wegovy 药丸：2026 年的游戏规则改变者</li>
</ul>
</div><p>A number of other large investors have also modified their holdings of LLY. Lazard Freres Gestion S.A.S. raised its stake in Eli Lilly and Company by 114.3% in the 2nd quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company's stock valued at $60,253,000 after purchasing an additional 41,222 shares during the last quarter. Precedent Wealth Partners LLC boosted its position in Eli Lilly and Company by 15.3% during the second quarter. Precedent Wealth Partners LLC now owns 294 shares of the company's stock worth $229,000 after acquiring an additional 39 shares during the last quarter. Central Pacific Bank Trust Division grew its stake in Eli Lilly and Company by 25.8% during the 3rd quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company's stock valued at $6,859,000 after acquiring an additional 1,843 shares in the last quarter. Capital Advisors Inc. OK grew its stake in Eli Lilly and Company by 6.8% during the 2nd quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company's stock valued at $5,260,000 after acquiring an additional 429 shares in the last quarter. Finally, Family CFO Inc acquired a new stake in Eli Lilly and Company in the 2nd quarter valued at about $54,000. Institutional investors and hedge funds own 82.53% of the company's stock.</p>
<div class="lb-trans"><p>其他一些大型投资者也调整了他们对 LLY 的持股。Lazard Freres Gestion S.A.S.在第二季度将其在礼来公司的股份增加了 114.3%。Lazard Freres Gestion S.A.S.现在拥有 77,295 股公司的股票，价值为 60,253,000 美元，此前在上个季度购买了 41,222 股。Precedent Wealth Partners LLC 在第二季度将其在礼来公司的持股增加了 15.3%。Precedent Wealth Partners LLC 现在拥有 294 股公司的股票，价值为 229,000 美元，此前在上个季度增加了 39 股。中央太平洋银行信托部在第三季度将其在礼来公司的股份增加了 25.8%。中央太平洋银行信托部现在拥有 8,990 股公司的股票，价值为 6,859,000 美元，此前在上个季度增加了 1,843 股。Capital Advisors Inc. OK 在第二季度将其在礼来公司的股份增加了 6.8%。Capital Advisors Inc. OK 现在拥有 6,747 股公司的股票，价值为 5,260,000 美元，此前在上个季度增加了 429 股。最后，Family CFO Inc 在第二季度获得了礼来公司的新股份，价值约为 54,000 美元。机构投资者和对冲基金持有公司 82.53% 的股票。</p>
</div><h2>Eli Lilly and Company Price Performance</h2>
<div class="lb-trans"><h2>礼来公司的价格表现</h2>
</div><p>LLY stock opened at $1,075.00 on Thursday. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,111.99. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The stock has a market cap of $1.02 trillion, a price-to-earnings ratio of 52.59, a price-to-earnings-growth ratio of 1.09 and a beta of 0.37. The business has a fifty day moving average of $1,003.00 and a two-hundred day moving average of $846.93.</p>
<div class="lb-trans"><p>LLY 股票在周四开盘价为 1,075.00 美元。礼来公司的 52 周低点为 623.78 美元，52 周高点为 1,111.99 美元。该公司的速动比率为 1.24，流动比率为 1.55，债务与股本比率为 1.71。该股票的市值为 1.02 万亿美元，市盈率为 52.59，市盈率增长比率为 1.09，贝塔值为 0.37。该公司的 50 日移动平均线为 1,003.00 美元，200 日移动平均线为 846.93 美元。</p>
</div><ul>
<li>Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么华尔街放弃了辉瑞——这可能是个错误</li>
</ul>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts' consensus estimates of $6.42 by $0.60. The business had revenue of $17.60 billion during the quarter, compared to analysts' expectations of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company's revenue was up 53.9% compared to the same quarter last year. During the same period in the prior year, the business posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.</p>
<div class="lb-trans"><p>礼来公司（NYSE:LLY - 获取免费报告）最近在 10 月 30 日星期四发布了季度财报。该公司报告本季度每股收益为 7.02 美元，超出分析师一致预期的 6.42 美元，超出幅度为 0.60 美元。该公司本季度的收入为 176 亿美元，而分析师预期为 160.9 亿美元。礼来公司的股本回报率为 109.52%，净利润率为 30.99%。与去年同期相比，该公司的收入增长了 53.9%。在去年同期，该公司每股收益为 1.18 美元。礼来公司已将其 2025 财年的指导目标设定为 23.000-23.700 每股收益。整体来看，研究分析师预计礼来公司今年将发布 23.48 美元的每股收益。</p>
</div><h2>Eli Lilly and Company Increases Dividend</h2>
<div class="lb-trans"><h2>礼来公司增加股息</h2>
</div><p>The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be given a dividend of $1.73 per share. This is a boost from Eli Lilly and Company's previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, February 13th. Eli Lilly and Company's dividend payout ratio (DPR) is 29.35%.</p>
<div class="lb-trans"><p>该公司最近宣布了一项季度股息，将于 3 月 10 日星期二支付。记录在案的股东将在 2 月 13 日星期五获得每股 1.73 美元的股息。这比礼来公司之前的季度股息 1.50 美元有所增加。这相当于每年 6.92 美元的股息，股息收益率为 0.6%。除息日期为 2 月 13 日星期五。礼来公司的股息支付比率（DPR）为 29.35%。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>Eli Lilly’s New Drug Data Sets Up a High-Stakes 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>礼来的新药数据为 2026 年设定了高风险赌注</li>
</ul>
</div><p>Several research analysts have recently weighed in on LLY shares. Sanford C. Bernstein restated an &#34;outperform&#34; rating on shares of Eli Lilly and Company in a report on Friday, December 19th. Bank of America reduced their price objective on Eli Lilly and Company from $1,286.00 to $1,268.00 and set a &#34;buy&#34; rating on the stock in a research report on Monday, December 15th. Wells Fargo &amp; Company upped their target price on Eli Lilly and Company from $1,100.00 to $1,200.00 and gave the company an &#34;overweight&#34; rating in a report on Wednesday, December 10th. HSBC reaffirmed a &#34;hold&#34; rating and issued a $1,070.00 target price on shares of Eli Lilly and Company in a research note on Wednesday, December 10th. Finally, Cantor Fitzgerald reiterated an &#34;overweight&#34; rating on shares of Eli Lilly and Company in a report on Monday, December 1st. Four investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $1,155.36.</p>
<div class="lb-trans"><p>几位研究分析师最近对 LLY 股票发表了看法。Sanford C. Bernstein 在 12 月 19 日星期五的报告中重申了对礼来公司股票的 “跑赢大盘” 评级。美国银行在 12 月 15 日的研究报告中将礼来公司的目标价从 1,286.00 美元下调至 1,268.00 美元，并对该股票给予 “买入” 评级。富国银行在 12 月 10 日的报告中将礼来公司的目标价从 1,100.00 美元上调至 1,200.00 美元，并给予该公司 “增持” 评级。汇丰银行在 12 月 10 日的研究报告中重申了 “持有” 评级，并对礼来公司的股票设定了 1,070.00 美元的目标价。最后，Cantor Fitzgerald 在 12 月 1 日的报告中重申了对礼来公司股票的 “增持” 评级。四位投资分析师对该股票给予了强烈买入评级，十七位给予了买入评级，五位给予了持有评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 1,155.36 美元。</p>
</div><p><strong>View Our Latest Research Report on Eli Lilly and Company</strong></p>
<div class="lb-trans"><p><strong>查看我们关于礼来公司的最新研究报告</strong></p>
</div><h2>Eli Lilly and Company Company Profile</h2>
<div class="lb-trans"><h2>礼来公司公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.</p>
<div class="lb-trans"><p>礼来公司 NYSE: LLY 是一家成立于 1876 年的全球制药公司，总部位于印第安纳州印第安纳波利斯。该公司研究、开发、生产和商业化广泛的药物和疗法，服务于全球患者。礼来在北美、欧洲、亚洲及其他地区开展业务并拥有商业存在，服务于发达市场和新兴市场。近年来，该公司由总裁兼首席执行官 David A.领导。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>The Best $1 You'll Spend This Holiday Season</li>
<li>Holiday surprise: $1 gets you everything</li>
<li>America’s “most deplorable” Christmas sale</li>
<li>Market Panic: Trump Just Dropped a Bomb on Your Stocks</li>
<li>Your family's wealth expires in 2026?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更喜欢的五只股票胜过礼来公司</li>
<li>这个假期你花 1 美元能买到的最好东西</li>
<li>假期惊喜：1 美元让你拥有一切</li>
<li>美国 “最糟糕” 的圣诞促销</li>
<li>市场恐慌：特朗普刚刚对你的股票投下了一颗炸弹</li>
<li>你家族的财富将在 2026 年到期？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding LLY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对 LLY 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com 获取 Eli Lilly and Company (NYSE:LLY - 免费报告) 的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=LLY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Eli Lilly and Company 吗？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Eli Lilly and Company 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Eli Lilly and Company 并不在名单上。</p>
</div><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Eli Lilly and Company 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

礼来公司 $LLY 的股票被弗吉尼亚退休系统等出售